Related Experiment Video
Updated: Apr 19, 2026
Skeletal Phenotype Analysis of a Conditional Stat3 Deletion Mouse Model
Published on: July 3, 2020
Abnormal mineralization of the Ts65Dn Down syndrome mouse appendicular skeleton begins during embryonic development
Joshua D Blazek1, Ahmed M Malik1, Maeve Tischbein2
1Department of Biology, Indiana University-Purdue University Indianapolis and Indiana University Center for Regenerative Biology and Medicine, 723 W. Michigan Street, SL306, Indianapolis, IN 46202, USA.
Abstract:
The relationship between gene dosage imbalance and phenotypes associated with Trisomy 21, including the etiology of abnormal bone phenotypes linked to Down syndrome (DS), is not well understood. The Ts65Dn mouse model for DS exhibits appendicular skeletal defects during adolescence and adulthood but the developmental and genetic origin of these phenotypes remains unclear. It is hypothesized that the postnatal Ts65Dn skeletal phenotype originates during embryonic development and results from an increased Dyrk1a gene copy number, a gene hypothesized to play a critical role in many DS phenotypes. Ts65Dn embryos exhibit a lower percent bone volume in the E17.5 femur when compared to euploid embryos. Concomitant with gene copy number, qPCR analysis revealed a ~1.5 fold increase in Dyrk1a transcript levels in the Ts65Dn E17.5 embryonic femur as compared to euploid. Returning Dyrk1a copy number to euploid levels in Ts65Dn, Dyrk1a(+/-) embryos did not correct the trisomic skeletal phenotype but did return Dyrk1a gene transcript levels to normal. The size and protein expression patterns of the cartilage template during embryonic bone development appear to be unaffected at E14.5 and E17.5 in trisomic embryos. Taken together, these data suggest that the dosage imbalance of genes other than Dyrk1a is involved in the development of the prenatal bone phenotype in Ts65Dn embryos.
Insights
Gene dosage imbalance in Down syndrome (DS) mouse models affects embryonic bone development. Other genes, not Dyrk1a, likely cause prenatal skeletal issues in DS embryos.
Area of Science:
- Genetics
- Developmental Biology
- Skeletal Biology
Background:
- The etiology of abnormal bone phenotypes in Down syndrome (DS) is poorly understood.
- The Ts65Dn mouse model displays skeletal defects, but their developmental origin is unclear.
- Dyrk1a gene dosage is hypothesized to contribute to DS phenotypes.
Purpose of the Study:
- To investigate the role of Dyrk1a gene dosage in the prenatal skeletal phenotype of the Ts65Dn mouse model for DS.
- To determine if Dyrk1a is the primary driver of skeletal abnormalities in DS embryos.
Main Methods:
- Comparison of bone volume in E17.5 femurs between Ts65Dn and euploid embryos.
- Quantitative PCR (qPCR) to measure Dyrk1a transcript levels.
- Genetic manipulation to normalize Dyrk1a copy number in Ts65Dn embryos.
Main Results:
- Ts65Dn embryos showed reduced femur bone volume at E17.5.
- Dyrk1a transcript levels were increased (~1.5 fold) in Ts65Dn embryonic femurs.
- Normalizing Dyrk1a copy number did not rescue the skeletal phenotype but normalized Dyrk1a transcript levels.
- Embryonic cartilage development appeared unaffected at E14.5 and E17.5.
Conclusions:
- The prenatal bone phenotype in Ts65Dn embryos is not solely caused by Dyrk1a gene dosage imbalance.
- Dosage imbalance of other genes likely contributes to skeletal abnormalities in DS during embryonic development.
